JEROME B. BLOCK, M.D.; PAUL P. CARBONE, M.D.; JOOST J. OPPENHEIM, M.D.; MIL FREI III, M.D.
The circulating leukocytes of patients with chronic myelogenous leukemia (CML) have decreased or absent leukocyte alkaline phosphatase (LAP) activity (1-3). Recently, it has been shown that these leukocytes have a high intracellular hydrogen ion concentration (4, 5) and diminished leukocyte acid excretion when compared with leukocytes from patients without hematologic disease (5-7). The relative effects of several chemotherapeutic agents on the magnitude and duration of response of hematologic and cytogenetic abnormalities in patients with CML have been presented in the preceding paper by Carbone et al. (8) in this issue of the ANNALS. The present report describes the effects of
BLOCK JB, CARBONE PP, OPPENHEIM JJ, et al. The Effect of Treatment in Patients with Chronic Myelogenous Leukemia: Biochemical Studies. Ann Intern Med. 1963;59:629–636. doi: 10.7326/0003-4819-59-5-629
Download citation file:
Published: Ann Intern Med. 1963;59(5_Part_1):629-636.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use